IRON
HEALTHCAREDisc Medicine Inc.
AI Insight
What's Moving IRON Today?
No stock-specific AI insight has been generated for IRON yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$40.00$99.50
$71.03
Fundamentals
Market Cap$2.7B
P/E Ratio—
EPS$-6.64
Dividend Yield—
Dividend / Share—
ROE-35.8%
Profit Margin—
Debt / Equity—
Trading
Volume367K
Avg Volume (10D)—
Shares Outstanding38.2M
IRON News
29 articles- Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual MeetingYahoo Finance·Jun 12, 2026
- Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic ProtoporphyriaYahoo Finance·Jun 9, 2026
- Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual MeetingYahoo Finance·Jun 2, 2026
- How Investors May Respond To Disc Medicine (IRON) Expanding Pre-Approval Access To Bitopertin For Porphyria PatientsYahoo Finance·Jun 1, 2026
- Disc Medicine Launches Expanded Access Program for Bitopertin for EPP PatientsYahoo Finance·Jun 1, 2026
- Disc Medicine Eyes Mid-2026 Bitopertin Approval as EPP Trial Demand SurgesMarketbeat·May 26, 2026
- Should Disc Medicine’s RALLY-MF Data and Wider Pipeline Reveal a Pivotal Inflection for IRON’s Narrative?Simply Wall Street·May 17, 2026
- Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 CongressYahoo Finance·May 12, 2026
- Disc Medicine to Participate in Upcoming Investor ConferencesYahoo Finance·May 11, 2026
- A Look At Disc Medicine (IRON) Valuation After Legal Probes And FDA Complete Response LetterYahoo Finance·May 6, 2026
- Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business UpdateYahoo Finance·May 5, 2026
- ROSEN, HIGHLY RANKED INVESTOR RIGHTS COUNSEL, Encourages ODDITY Tech Ltd. Investors With Losses in Excess of $100k to Secure Counsel Before Important Deadline in Securities Class Action– ODDGlobeNewswire Inc.·Apr 25, 2026
- IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your RightsGlobeNewswire Inc.·Apr 25, 2026
- Polycythemia Vera Market Set for Transformation: Key 9 Companies Expected to Enter by 2036 | DelveInsightGlobeNewswire Inc.·Apr 22, 2026
- Disc Medicine Insider Sells $380K in Stock Amid 70% One-Year SurgeMotley Fool·Apr 21, 2026
- Disc Medicine Announces Oral Presentation of Data from RALLY-MF Phase 2 Trial of DISC-0974 in Patients with Myelofibrosis and Anemia at the American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswire Inc.·Apr 21, 2026
- IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your RightsGlobeNewswire Inc.·Apr 19, 2026
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc. - IRONGlobeNewswire Inc.·Apr 7, 2026
- IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your RightsGlobeNewswire Inc.·Mar 27, 2026
- Disc Medicine, Inc. Investigated by the Portnoy Law FirmGlobeNewswire Inc.·Mar 27, 2026
- Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic ProtoporphyriaYahoo Finance·Mar 26, 2026
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Disc Medicine, Inc. – IRONGlobeNewswire Inc.·Mar 24, 2026
- Evaluating Disc Medicine (IRON) After Recent Share Moves And Conflicting Valuation SignalsYahoo Finance·Mar 11, 2026
- What 3 recent FDA rejections reveal about shifts inside the agencyPharmavoice·Mar 4, 2026
- Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsightYahoo Finance·Mar 3, 2026
- Disc Medicine CFO Sells $720k Worth of Shares Amid FDA RejectionMotley Fool·Mar 1, 2026
- Disc Medicine (IRON) Is Up 8.6% After Wider 2025 Losses And New Shelf Registration - What's ChangedYahoo Finance·Feb 28, 2026
- Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateYahoo Finance·Feb 26, 2026
- Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows ConvictionMotley Fool·Feb 25, 2026
All 29 articles loaded
Price Data
Open$70.27
Previous Close$70.80
Day High$72.49
Day Low$70.27
52 Week High$99.50
52 Week Low$40.00
52-Week Range
$40.00$99.50
$71.03
Fundamentals
Market Cap$2.7B
P/E Ratio—
EPS$-6.64
Dividend Yield—
Dividend / Share—
ROE-35.8%
Profit Margin—
Debt / Equity—
Trading
Volume367K
Avg Volume (10D)—
Shares Outstanding38.2M
About Disc Medicine Inc.
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The company is headquartered in Watertown, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—